Biospecifics Technologies (BSTC) Tops Q1 EPS by 3c

Biospecifics Technologies (NASDAQ: BSTC) reported Q1 EPS of $0.40, $0.03 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 million versus the consensus estimate of $6.25 million.

For earnings history and earnings-related data on Biospecifics Technologies (BSTC) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Keefe, Bruyette & Woods Starts Columbia Financial Inc (CLBK) at Outperform
• Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform